201 related articles for article (PubMed ID: 10661476)
1. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[TBL] [Abstract][Full Text] [Related]
3. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
McIntyre CW; Fluck RJ; Lambie SH
Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
[TBL] [Abstract][Full Text] [Related]
4. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.
Mitsuiki K; Harada A; Okura T; Higaki J
Clin Exp Nephrol; 2007 Dec; 11(4):297-303. PubMed ID: 18085391
[TBL] [Abstract][Full Text] [Related]
5. Can immunosuppressive drugs slow the progression of IgA nephropathy?
Goumenos D; Ahuja M; Shortland JR; Brown CB
Nephrol Dial Transplant; 1995; 10(7):1173-81. PubMed ID: 7478120
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of two cyclophosphamide treatment regimens in nephrotic patients with chronic glomerulonephritis].
Krasnova TN; Shilov EM; Tareeva IE; Gordovskaia NB; Lavrova ON; Miroshnichenko NG; Troepol'skaia OV; Ivanova LV; Ivanov AA
Ter Arkh; 1998; 70(6):14-7. PubMed ID: 9695216
[TBL] [Abstract][Full Text] [Related]
7. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria.
Uzu T; Harada T; Ko M; Yamato M; Takahara K; Yamauchi A
Clin Exp Nephrol; 2003 Sep; 7(3):210-4. PubMed ID: 14586717
[TBL] [Abstract][Full Text] [Related]
8. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function.
Tamura S; Ueki K; Ideura H; Tsukada Y; Maezawa A; Kawai H; Wakamatsu R; Yano S; Nojima Y; Naruse T
Clin Nephrol; 2001 Mar; 55(3):192-5. PubMed ID: 11316238
[TBL] [Abstract][Full Text] [Related]
10. A validated model of disease progression in IgA nephropathy.
Magistroni R; Furci L; Leonelli M; Masellis M; Ligabue G; Lucchi L; Lupo A; Brezzi B; Gambaro G; Manganelli L; Pedrazzi G; Ricardi M; Bormioli L; Albertazzi A
J Nephrol; 2006; 19(1):32-40. PubMed ID: 16523423
[TBL] [Abstract][Full Text] [Related]
11. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial.
Kanno Y; Witt M; Okada H; Nemoto H; Sugahara S; Nakamoto H; Suzuki H
Clin Exp Nephrol; 2003 Mar; 7(1):48-51. PubMed ID: 14586743
[TBL] [Abstract][Full Text] [Related]
12. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
Komatsu H; Fujimoto S; Sato Y; Hara S; Yamada K; Morita S; Eto T
J Nephrol; 2005; 18(6):690-5. PubMed ID: 16358226
[TBL] [Abstract][Full Text] [Related]
13. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.
Hotta O; Miyazaki M; Furuta T; Tomioka S; Chiba S; Horigome I; Abe K; Taguma Y
Am J Kidney Dis; 2001 Oct; 38(4):736-43. PubMed ID: 11576876
[TBL] [Abstract][Full Text] [Related]
14. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
Walker RG; Yu SH; Owen JE; Kincaid-Smith P
Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
[TBL] [Abstract][Full Text] [Related]
15. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
[TBL] [Abstract][Full Text] [Related]
16. Treatment of vasculitic IgA nephropathy.
Harper L; Ferreira MA; Howie AJ; Savage CO; Richards NT; Michael J; Adu D
J Nephrol; 2000; 13(5):360-6. PubMed ID: 11063140
[TBL] [Abstract][Full Text] [Related]
17. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of intensive therapy combined with tonsillectomy in patients with IgA nephropathy.
Hotta O; Taguma Y; Yoshizawa N; Oda T; Nishiyama J; Yusa N; Chiba S; Horigome I; Sudo K; Tomioka S
Acta Otolaryngol Suppl; 1996; 523():165-8. PubMed ID: 9082770
[TBL] [Abstract][Full Text] [Related]
19. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome.
Eguchi A; Takei T; Yoshida T; Tsuchiya K; Nitta K
Nephrol Dial Transplant; 2010 Jan; 25(1):124-9. PubMed ID: 19740915
[TBL] [Abstract][Full Text] [Related]
20. [The course and prognosis of mesangioproliferative glomerulonephritis].
Shilov EM; Tareeva IE; Ivanov AA; Troepol'skaia OV; Krasnova TN; Varshavskiĭ VA; Proskurneva EP; Ivanova LV; Khudova IIu; Miroshnichenko NG
Ter Arkh; 2002; 74(6):11-8. PubMed ID: 12136475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
